GR1003861B - Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. - Google Patents
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.Info
- Publication number
- GR1003861B GR1003861B GR20000100470A GR2000100470A GR1003861B GR 1003861 B GR1003861 B GR 1003861B GR 20000100470 A GR20000100470 A GR 20000100470A GR 2000100470 A GR2000100470 A GR 2000100470A GR 1003861 B GR1003861 B GR 1003861B
- Authority
- GR
- Greece
- Prior art keywords
- present
- anxiety
- neurosteroids
- formula
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
παρούσα εφεύρεση αναφέρεται σε νέα ανάλογα στεροειδών τα οποία επιδρούν στον ιοντοφόρο σύμπλεγμα υποδοχέας γ-αμινοβουτυρικού οξέος-κανάλι χλωρίου καθώς επίσης και μεθόδους για τη σύνθεση αυτών και εφαρμογή τους σαν αναισθητικά, για την αντιμετώπιση του stress, άγχους, αυπνίας, επιληψίας , PMS, PDN και για τη βελτίωση ή πρόληψη επεισοδίων άγχους, μυικής τάσης και κατάθλιψης οι οποίες είναι καταστάσεις που απαντώνται σε ασθενείς που υποφέρουν απο διαταραχές του κεντρικού νευρικού συστήματος.
Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) όπου τα R1,R2,R3,R4,R5 προσδιορίζονται στην Περιγραφή της εφεύρεσης Επίσης μέρος της εφεύρεσης αποτελούν και φαρμακοτεχνικές μορφές που περιλαμβάνουν μία ή και περισσότερες απο τις ενώσεις του τύπου (Ι). ΰ
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20000100470A GR1003861B (el) | 2000-12-29 | 2000-12-29 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. |
US10/250,334 US7064116B2 (en) | 2000-12-29 | 2001-12-21 | GABAA modulating neurosteroids |
AU2002217353A AU2002217353A1 (en) | 2000-12-29 | 2001-12-21 | Gabaa modulating neurosteroids |
PCT/GR2001/000048 WO2002053577A2 (en) | 2000-12-29 | 2001-12-21 | Gabaa modulating neurosteroids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20000100470A GR1003861B (el) | 2000-12-29 | 2000-12-29 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. |
Publications (1)
Publication Number | Publication Date |
---|---|
GR1003861B true GR1003861B (el) | 2002-04-11 |
Family
ID=10944475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20000100470A GR1003861B (el) | 2000-12-29 | 2000-12-29 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. |
Country Status (4)
Country | Link |
---|---|
US (1) | US7064116B2 (el) |
AU (1) | AU2002217353A1 (el) |
GR (1) | GR1003861B (el) |
WO (1) | WO2002053577A2 (el) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
AU2009219230A1 (en) * | 2008-02-26 | 2009-09-03 | Emory University | Steroid analogues for neuroprotection |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CZ302050B6 (cs) * | 2009-08-04 | 2010-09-15 | Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. | 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití |
AU2011284606A1 (en) * | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
CN113956315B (zh) | 2011-09-08 | 2024-08-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
NZ627781A (en) | 2012-01-23 | 2016-10-28 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
WO2014085668A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
TR201808616T4 (tr) | 2012-12-18 | 2018-07-23 | Sage Therapeutics Inc | Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri. |
US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
EP3932932A1 (en) * | 2013-03-13 | 2022-01-05 | Sage Therapeutics, Inc. | Neuroactive steriods and methods of use thereof |
US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
HUE041369T2 (hu) | 2013-04-17 | 2019-05-28 | Sage Therapeutics Inc | 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
CA3199003A1 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CA3235088A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
MX2017005002A (es) | 2014-10-16 | 2018-01-23 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc. |
US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
MX2020011449A (es) | 2015-07-06 | 2022-02-28 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
CA2991313C (en) | 2015-07-06 | 2023-12-19 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10696712B2 (en) | 2015-07-06 | 2020-06-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
KR102408399B1 (ko) | 2016-03-08 | 2022-06-13 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
AU2017240157B2 (en) | 2016-04-01 | 2022-10-20 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MD3481846T2 (ro) | 2016-07-07 | 2021-11-30 | Sage Therapeutics Inc | 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA |
IL309259A (en) | 2016-07-11 | 2024-02-01 | Sage Therapeutics Inc | C17, C20 and C21 converted neuroactive steroids and methods of using them |
JP7065825B2 (ja) | 2016-07-11 | 2022-05-12 | セージ セラピューティクス, インコーポレイテッド | C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法 |
CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
NZ752732A (en) | 2016-10-18 | 2024-08-30 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
AU2017345399B2 (en) | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MA56046A (fr) | 2019-05-31 | 2022-04-06 | Sage Therapeutics Inc | Stéroïdes neuroactifs et compositions associées |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1430942A (en) * | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
WO1994027608A1 (en) * | 1993-05-24 | 1994-12-08 | Cocensys, Inc. | Methods and compositions for inducing sleep |
WO1996040043A2 (en) * | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
-
2000
- 2000-12-29 GR GR20000100470A patent/GR1003861B/el unknown
-
2001
- 2001-12-21 AU AU2002217353A patent/AU2002217353A1/en not_active Abandoned
- 2001-12-21 US US10/250,334 patent/US7064116B2/en not_active Expired - Lifetime
- 2001-12-21 WO PCT/GR2001/000048 patent/WO2002053577A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1430942A (en) * | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
WO1994027608A1 (en) * | 1993-05-24 | 1994-12-08 | Cocensys, Inc. | Methods and compositions for inducing sleep |
WO1996040043A2 (en) * | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
Non-Patent Citations (2)
Title |
---|
ERCOLI ET AL: "Sugli Acidi Biliari e loro Derivati. Nota IV - Un Nouvo Metodo di Demolizione Graduale. Sua Applicazione alla Degradazione dell'Acido Litocolico", FARMACO., vol. 6, 1951, SOCIETA CHIMICA ITALIANA, PAVIA., IT, pages 547, XP001025589, ISSN: 0014-827X * |
PETTIT G R ET AL: "BUFADIENOLIDES. 13. CONVERSION OF 3BETA-HYDROXY-17-OXOANDROST-5-ENE TO 3BETA-ACETOXY-5BETA,14ALPHA-BUFA-20,22-DIENOLIDE", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 36, no. 21, 22 October 1971 (1971-10-22), pages 3207 - 3211, XP002029626, ISSN: 0022-3263 * |
Also Published As
Publication number | Publication date |
---|---|
US20050176976A1 (en) | 2005-08-11 |
WO2002053577A2 (en) | 2002-07-11 |
WO2002053577A3 (en) | 2002-10-10 |
US7064116B2 (en) | 2006-06-20 |
AU2002217353A1 (en) | 2002-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR1003861B (el) | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
ATE463247T1 (de) | Bupropion metaboliten zur behandlung von angstzuständen | |
HUP0401108A2 (hu) | Spirovegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
YU45403A (sh) | Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida | |
TNSN07021A1 (fr) | Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc | |
EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
NZ544591A (en) | Pyrrolodihydroisoquinolines as PDE10 inhibitors | |
YU63202A (sh) | Derivati 2-okso-1-pirolidina, postupci za njihovo dobijanje i njihove upotrebe | |
RS20050744A (en) | Benzopyran compounds useful for treating inflammatory conditions | |
MA27769A1 (fr) | Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique | |
HK1129103A1 (en) | Prodrugs of gaba analogs, compositions and uses thereof gaba | |
MX2007013263A (es) | Novedosos derivados oxadiazol y su uso medico. | |
HK1068628A1 (en) | Nicotinic acetyl-choline receptors inhibitor compounds, their preparation and use | |
ATE348831T1 (de) | Diazabicyclische biarylderivate | |
DE60309740D1 (de) | 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung | |
TW200504045A (en) | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | |
MX2007012624A (es) | Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a. | |
AU2002224847A1 (en) | N-alkylated gaba compounds, processes for their preparation and their use as medicaments | |
WO2004047727A3 (en) | Compositions and methods for diagnosing and treating mood disorders | |
MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
BR0011039A (pt) | Análogos de gaba substituìdos com 3-heteroarilalquila | |
WO2001080845A3 (en) | (2-aminoethyl) oxime derivatives for the treatment of depression | |
ATE283838T1 (de) | Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung |